

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Proposed Single Technology Appraisal

#### Rivaroxaban for preventing major cardiovascular events in people with coronary or peripheral artery disease ID1397

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Bayer (rivaroxaban)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Blood Pressure UK</li> <li>• Cardiac Risk in the Young</li> <li>• Cardiovascular Care Partnership</li> <li>• Coronary Prevention Group</li> <li>• Different Strokes</li> <li>• HEART UK</li> <li>• Muslim Council of Britain</li> <li>• Network of Sikh Organisations</li> <li>• Pumping Marvellous</li> <li>• Somerville Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Stroke Association</li> <li>• The Circulation Foundation</li> <li>• Thrombosis UK</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for Nursing in Cardiovascular Care</li> <li>• British Association of Stroke Physicians</li> <li>• British Atherosclerosis Society</li> <li>• British Cardiovascular Society</li> <li>• British Cardiovascular Intervention Society</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Heart Rhythm Society</li> <li>• British Hypertension Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (aspirin, clopidogrel)</li> <li>• Alliance Pharmaceuticals (aspirin)</li> <li>• Actavis UK (clopidogrel)</li> <li>• AstraZeneca (ticagrelor)</li> <li>• Aurobindo Pharma – Milpharm (clopidogrel)</li> <li>• Concordia International (aspirin)</li> <li>• Dexcel Pharam (aspirin)</li> <li>• Dr Reddy's Laboratories (aspirin)</li> <li>• Glaxosmithkline consumer healthcare (aspirin)</li> <li>• Intrapharm Laboratories (aspirin)</li> <li>• Kent Pharmaceuticals (clopidogrel)</li> </ul>

Provisional matrix for the proposed technology appraisal of rivaroxaban for preventing major cardiovascular events in people with coronary or peripheral artery disease ID1397

Issue date: May 2018

© National Institute for Health and Care Excellence 2018. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Institute of Radiology</li> <li>• British Nuclear Cardiology Society</li> <li>• British Society for Cardiovascular Research</li> <li>• British Society for Haematology</li> <li>• British Society for Haemostasis and Thrombosis</li> <li>• British Society for Heart Failure</li> <li>• British Society of Cardiac Radiology</li> <li>• British Society of Cardiovascular Imaging</li> <li>• British Society of Rehabilitation Medicine</li> <li>• British Thoracic Society</li> <li>• Chartered Society of Physiotherapy</li> <li>• Clinical Leaders of Thrombosis</li> <li>• Physiotherapy Pain Association</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of Emergency Medicine</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science and Technology</li> <li>• Society of Vascular Nurses</li> <li>• Society for Vascular Technology</li> <li>• TREND UK</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Health Forum</li> <li>• Vascular Society of Great Britain and Ireland</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Bedfordshire CCG</li> <li>• NHS Calderdale CCG</li> <li>• NHS England</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Martindale Pharma (aspirin)</li> <li>• Pfizer Consumer Healthcare (aspirin)</li> <li>• Reckitt Benckiser Healthcare UK (aspirin)</li> <li>• Sandoz (clopidogrel)</li> <li>• Sanofi (clopidogrel)</li> <li>• Teva UK (aspirin)</li> <li>• Thornton and Ross (aspirin)</li> <li>• Zentiva (aspirin, clopidogrel)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Cardiovascular Research</li> <li>• Cardiac and Cardiology Research Dept, Barts</li> <li>• Central Cardiac Audit Database</li> <li>• Cochrane Heart Group</li> <li>• Cochrane Hypertension Group</li> <li>• Cochrane Peripheral Vascular Diseases Group</li> <li>• Cochrane Stroke Group</li> <li>• European Council for Cardiovascular Research</li> <li>• Heart Research UK</li> <li>• MRC Clinical Trials Unit</li> <li>• National Centre for Cardiovascular Preventions and Outcomes</li> <li>• National Institute for Health Research</li> <li>• The Society for Research in Rehabilitation</li> <li>• Wellcome Trust</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.